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commenting on the lack of predictive value of donor chimerism assessment on the outcome of patients receiving alemtuzumab-based conditioning. The evaluation of donor chimerism following allogeneic SCT, particularly following reduced-intensity conditioning regimens, has developed into an important tool for predicting graft failure as well as a guide toward the use of donor lymphocytes infusions. 2, 3 Its role in predicting other transplant outcomes such as disease relapse or GVHD is much less defined. 2, 3 Advances in chimerism analysis have facilitated the use of lineage-specific analysis of peripheral blood subsets, and several studies to date have demonstrated a degree of correlation between the kinetics of T-cell engraftment post HSCT and transplant outcomes. [4] [5] [6] In particular, various groups have reported an association between early attainment of full donor T-cell chimerism and an increased incidence of acute GVHD. [5] [6] [7] [8] In contrast, while some early studies have linked the presence of early mixed donor chimerism to subsequent relapse, these data have been both confirmed and contradicted in other studies. 9, 10 We recently evaluated the results of 110 patients receiving alemtuzumab-based reduced intensity conditioning for MDS and AML, using a regimen of 30 mg/m 2 i.v. fludarabine daily from day À9 to day À5; 4 mg/kg oral BU in four divided doses daily from day À3 to day À2; and 20 mg i.v. alemtuzumab daily from day À8 to day À4. Chimerism was assessed in isolated peripheral blood CD3 þ T cell and CD15 þ granulocyte populations as well as unfractionated BM samples. DNA was extracted using the QIAamp DNA Blood Mini Kit (QIAGEN) and fifteen polymorphic STR loci (Penta E, D18S51, D21S11, TH01, D3S1358, FGA, TPOX, D8S1179, vWA, Penta D, CSF1PO, D16S539, D7S820, D13S317 and D5S818) plus the sex determining amelogenin loci (PowerPlex, Promega Corp., Madison, WI, USA) were amplified to provide a genetic profile for pre-transplant donor and recipient samples. Informative alleles were identified and used to assess donor engraftment. The samples were electrophoresed using PAGE on an ABI Prism 377 DNA sequencer and analysed using Genescan 2.0 software (Applied Biosystems, Foster City, CA, USA). Quantification was carried out using the area under the peaks and following cell dilution studies the sensitivity of this methodology is approximately 5%.
Similar to results reported by Michaelis et al., 1 we found no correlation between unfractionated BM and peripheral blood chimerism and transplant outcomes. However, on analysis of T-cell (CD3) chimerism, we observed that patients achieving full donor chimerism (FDC) by day þ 100 (n ¼ 46) had an increased incidence of GVHD, higher transplant-related mortality and poorer overall survival (OS). In contrast, patients in our cohort with mixed donor chimerism (MDC, n ¼ 59) at day þ 100 had a more favourable outcome (2-year OS, disease-free survival (DFS) and TRM of 69.7 vs 43.5% (P ¼ 0.03), 65.4 vs 43.7% (P ¼ 0.03) and 8.7 vs 37.2% (Po0.01)) and did not have an increased relapsed incidence when compared to patients attaining early FDC (MDC: 27.1% vs FDC: 25.1%, P ¼ 0.73). This is consistent with data published by Montero et al.
9 using T-cell depletion in a myeloablative conditioning regimen, where patients with persistent mixed donor chimerism (MDC) had no increased risk of disease relapse. In both studies, patients with MDC were considered for pre-emptive donor lymphocyte infusions (DLI). In the Montero study, patients with mixed T-cell chimerism received DLI at day 45 and in some cases day 90, whereas in our study, patients with o50% donor T-cell chimerism at day 100 (n ¼ 28) were considered for incremental doses of pre-emptive DLI. As such, it is possible in both these studies that disease relapse was not increased as patients with MDC were more likely to go on to receive a DLI than those with full donor T-cell chimerism. However, we also identified a cohort of 22 patients in our study who had an extended period of stable T-cell MDC without needing DLI. Only five patients have since converted to FDC at a median of 1 year, with the majority of patients having a persisting high level of stable donor chimerism (470%). While there was no difference in overall outcomes between patients with stable MDC or those receiving pre-emptive DLI in our study, both groups had an improved DFS when compared to patients achieving FDC by day 100 (43 vs 76%, P ¼ 0.02, and 43 vs 77%, Po0.01 respectively). In contrast, Mohty et al. 11 have recently reported a cohort of 102 patients who received a fludaraine, BU and antithymocyte globulin (ATG) regimen, observing that rapid FDC in T-cell chimerism was associated with an increased risk of GVHD, and that within a subgroup of patients with myeloid malignancies, prolonged MDC was associated with a higher relapse risk. 11 These findings suggest that the kinetics of immune reconstitution differ significantly not only between patients receiving T-cell depleted and T-cell replete conditioning regimens, but that even within T-cell depletion regimens, the type of agent, be it ATG or alemtuzumab, may have a significant influence on the interpretation of chimerism results. Caution should be applied in the interpretation of results from cohorts of patients with mixed haematological disorders using non-lineage-specific chimerism results. At present, it remains unclear if T-cell chimerism is a direct predictor of transplant outcomes, or a surrogate marker for other transplant variables, and prospective research into the use of lineage-specific chimerism directed toward specific haematological diseases is warranted in order to attain informative interpretation of chimerism results and guide appropriate clinical responses. 
